6915-96-4Relevant academic research and scientific papers
SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents
Awasthi, Divya,Kumar, Kunal,Knudson, Susan E.,Slayden, Richard A.,Ojima, Iwao
, p. 9756 - 9770 (2013)
FtsZ, an essential protein for bacterial cell division, is a highly promising therapeutic target, especially for the discovery and development of new-generation anti-TB agents. Following up the identification of two lead 2,5,6-trisubstituted benzimidazole
Benzimidazole-based antibacterial agents against Francisella tularensis
Kumar, Kunal,Awasthi, Divya,Lee, Seung-Yub,Cummings, Jason E.,Knudson, Susan E.,Slayden, Richard A.,Ojima, Iwao
, p. 3318 - 3326 (2013/07/05)
Francisella tularensis is a highly virulent pathogenic bacterium. In order to identify novel potential antibacterial agents against F. tularensis, libraries of trisubstituted benzimidazoles were screened against F. tularensis LVS strain. In a preliminary
Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents
Kumar, Kunal,Awasthi, Divya,Lee, Seung-Yub,Zanardi, Ilaria,Ruzsicska, Bela,Knudson, Susan,Tonge, Peter J.,Slayden, Richard A.,Ojima, Iwao
supporting information; experimental part, p. 374 - 381 (2011/03/18)
Libraries of novel trisubstituted benzimidazoles were created through rational drug design. A good number of these benzimidazoles exhibited promising MIC values in the range of 0.5-6 μg/mL (2-15 μM) for their antibacterial activity against Mtb H37Rv strai
BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page/Page column 13, (2008/12/08)
The present invention relates to novel benzimidazole derivatives and pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating a patient infected by Mycobacterium tuberculosis or Francisella tulerensis by ad
